# Empowerment-based case management for treatment-resistant schizophrenia: a three-year single case report

**Authors:** Cong Wang, Xianbin Li, Jinsong Chen, Xiaohong Li, Wenpeng Hou, Ning Dong

PMC · DOI: 10.3389/fpsyt.2026.1760312 · Frontiers in Psychiatry · 2026-02-09

## TL;DR

A three-year case study shows that an empowerment-based approach can improve outcomes for a patient with treatment-resistant schizophrenia.

## Contribution

This study introduces a novel four-dimensional empowerment framework for managing treatment-resistant schizophrenia.

## Key findings

- PANSS total score decreased from 90 to 61 over three years.
- CGI severity score reduced from 6 to 3, indicating improved clinical status.
- Qualitative results showed increased autonomy, reduced stigma, and better family dynamics.

## Abstract

This case report describes the implementation and observed outcomes of an empowerment-oriented case management approach in a patient with treatment-resistant schizophrenia (TRS), addressing the limitations of conventional approaches that often neglect patient autonomy and subjective agency. Through the implementation of a multidisciplinary, four-dimensional empowerment framework—comprising pathological treatment, psychological cognition, social engagement, and family care—a 34-year-old male TRS patient received targeted intervention over a three-year period. Quantitative assessments, including PANSS, HRSD, SDSS, CGI, MRSS, and FAES II-CV, demonstrated substantial improvements: PANSS total score decreased from 90 to 61, CGI severity score reduced from 6 to 3, and MRSS dependency subscale declined from 29 to 14. Qualitative interviews further revealed enhanced medication adherence, symptom self-monitoring, and social functioning, alongside increased daily autonomy, reduced stigma, and improved family dynamics. These preliminary observations from a single case suggest potential benefits that warrant systematic investigation through controlled studies. The temporal associations observed between the intervention and improvements cannot establish causality but provide hypotheses for future research.

## Linked entities

- **Diseases:** schizophrenia (MONDO:0005090)

## Full-text entities

- **Diseases:** confusion (MESH:D003221), Medication Negotiation (MESH:D000069279), psychopaths (MESH:D000987), HAMD (MESH:C538175), disease (MESH:D004194), Schizophrenia (MESH:D012559), anxiety (MESH:D001007), paranoid delusions (MESH:D010259), mental disability (MESH:D001523), executive dysfunction (MESH:D006331), Depression (MESH:D003866), impairment of social functions (OMIM:300082), social anxiety (MESH:D000072861), cognitive, thought, emotional, and behavioral dysfunctions (MESH:D003072), -resistant schizophrenia (MESH:D000090663), mental disease (MESH:D008607), delusions (MESH:D063726), symptom (MESH:D012816), auditory hallucinations (MESH:D006212), psychosis (MESH:D011618), restlessness (MESH:D011595)
- **Chemicals:** risperidone (MESH:D018967), cholesterol (MESH:D002784), Clozapine (MESH:D003024), aripiprazole (MESH:D000068180), olanzapine (MESH:D000077152), sertraline (MESH:D020280)
- **Species:** Oryza sativa (Asian cultivated rice, species) [taxon 4530], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12926766/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12926766/full.md

## References

29 references — full list in the complete paper: https://tomesphere.com/paper/PMC12926766/full.md

---
Source: https://tomesphere.com/paper/PMC12926766